President of Q BioMed Inc. Expands on Corporate Update in

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
President of Q BioMed Inc. Expands on Corporate Update in Q&A

POINT ROBERTS, WA --(Marketwired - March 21, 2016) -  Investorideas.com, a digital global news source covering leading sectors including medical technology and biotech stocks releases a recent interview with Mr. Denis Corin, President of Q BioMed Inc. ( OTCQB : QBIO ). Denis expands on the recent corporate update and Scrip Intelligence Video released in late February. He also comments on recent developments with Mannin Research Inc's leading glaucoma drug candidate MAN-01. (In October 2015 Q BioMed Inc. entered into an agreement with Mannin Research to exclusively license, with an option to acquire, the platform technology assets of Mannin Research, the developer of a new class of vascular therapeutics.)

Q&A Q: Investorideas.com

Denis, your company's strategy is to acquire companies and biomedical assets. Can you expand on that and also share what assets have been acquired or licensed to date?

A: Mr. Denis Corin, President of Q BioMed Inc.

Sure, our mission is to license and acquire innovative life sciences assets from academia or small private companies and provide the strategic resources including financial capital, intellectual capital, business development and scientific advice to accelerate their product development timelines to commercialize their drug candidates or bring them to the next level in terms of valuation inflection.

We have identified several targets that we believe could provide a substantial pipeline of innovative and high value assets. We will aim to maximize risk-adjusted returns by focusing on multiple assets throughout the discovery and development cycle, so we'll have assets in pre-clinical, clinical and commercial stages. This allows a nice flow of development news and value drivers as they all move through their paces. We expect to benefit from early positioning in illiquid and/or unknown private assets with multiple potential products in their development cycle and to capitalize on valuation growth as they move forward in their development. We believe this gives investors a unique opportunity to participate in the growth and development of these assets and the value they bring to the overall pipeline.

In the last quarter of 2015, we entered into an exclusive License and Purchase Option Agreement with Mannin Research Inc. whereby we were granted a worldwide, exclusive license, with the option to acquire their platform assets for Glaucoma and other indications. The Mannin IP and technology platform is initially focused on developing a first-in-class eye drop treatment for glaucoma. The technology platform may be expanded in scope beyond Glaucoma as well as beyond ophthalmological uses and may include cystic kidney disease and others.

This is an area of therapy that urgently needs a new offering. No new drugs in this particular indication have been successfully brought to this market for over 20 years.

The global market for Glaucoma therapeutics is one of the largest segments of the $23 billion global ophthalmology market. There are 60 million people worldwide suffering from Glaucoma. It is projected that the total population suffering from Glaucoma will grow to 80 million by 2020 (W.H.O 2010), so there is an acute need for this type of drug in a very lucrative market. Our lead candidate, MAN-01, will address this market as a first-in-class drug that treats abnormal vessels within the eye, thereby treating Glaucoma at its root causes. 

There is no cure for Glaucoma and new therapeutics are highly sought after. Current therapies and surgical procedures are not optimally effective, are painful and not well tolerated by patients.

Together with Mannin, we are developing a unique molecule in the form of an easy-to-administer eye drop, designed to repair the normal flow of fluid in the eye and resulting in the reduction of intraocular pressure (IOP), one of the main causes of Glaucoma. Our platform is both unique and first-in-class and we are the only drug company targeting this method of action.

IOP caused by abnormal flow of clear fluid within the eye damages the nerves in the eye, eventually leading to blindness. A specialized blood vessel, the 'Schlemm's Canal' is the major drainage pathway for fluid to escape from the front of the eye. Glaucoma can occur when this canal is either blocked or from a birth defect, resulting in a small or absent Schlemm's Canal. Our drug candidate would target the organization of the Schlemms Canal on a cellular level, thereby creating the optimal environment for 'repair' and improved flow and ultimately, lower IOP.

Given the large 23 Billion dollar ophthalmology market and the acute need for these types of drugs, we believe there is a substantial opportunity here. In addition, a deep pipeline of novel therapeutics can be developed from this research platform, developed and lead by Dr. Quaggin, which would treat a spectrum of vascular diseases including Cystic Kidney disease.

So to sum up, while this is an earlier stage pre-clinical asset, we see tremendous opportunity here and look forward to building value in it as we advance.

Q: Investorideas.com

Can you tell us about your recent addition to management, Mr. David Laskow-Pooley, as VP Scientific & Product Development, and the value added to your team in seeking new products for your pipeline?

A: Mr. Denis Corin, President of Q BioMed Inc.

David is an industry veteran with a very broad-based and deep knowledge. We are very pleased to have him on board with us. He has 30 years of experience in all aspects of the discovery, development and commercialization of pharmaceutical products, diagnostics and devices. He has a distinguished career working for numerous pharmaceutical and life sciences companies. David has held director, executive officer and general management posts in both small and major multinational companies including GSK, Abbott, Amersham plc, Life Technologies, OSI, Bilcare and Surface Therapeutics.

David brings tremendous operational value to us as we look at commercializing assets and advancing them through the development life cycle. He has some very deep and unique experiences that will fit perfectly with some of the assets we are currently evaluating.

Q: Investorideas.com

Can you talk about Mannin Research Inc's Glaucoma treatment technology and its lead drug candidate MAN-01 and the progress it is making?

A: Mr. Denis Corin, President of Q BioMed Inc

Mannin Research's (Mannin) Glaucoma therapeutic is a first-in-class therapeutic designed to treat Primary Open-Angle Glaucoma. It is based on the research by Dr. Susan Quaggin, Director of the Feinberg Cardiovascular Research Institute and Chief of the Division of Nephrology and Hypertension at Northwestern University. The MAN-01 therapeutic is an important molecule in the context of new pharmaceuticals that can treat Glaucoma. Mannin's therapeutic will address increased intraocular pressure in the eye by acting on a vessel in the eye called the Schlemm's Canal, which is a main drainage path for the eye. Mannin is currently in the pre-clinical phase. Optimizing the molecule, we aim to use it in the clinic in late 2017/early 2018. There we are looking at demonstrating the effectiveness of this therapeutic in lowering intraocular pressure (IOP). We are making good progress and are on track to meet our internal milestones.

Q: Investorideas.com

Aerie Pharmaceuticals, Inc. reported safety results recently from a trial testing its Glaucoma treatment. Can you give us a quick differentiation in technology and approach between Mannin's MAN-01 and Aerie Pharmaceuticals treatment?

A: Mr. Denis Corin, President of Q BioMed Inc.

 Aerie's approach to treatment in Glaucoma, like ours, is to reduce IOP, which is the gold standard in measuring the effectiveness of Glaucoma's therapeutics. Aerie's mechanism of action (MOA) is the Rock/NET pathway which acts primarily on the Tubercular Meshwork, best described as a 'sieve' that sits on top of the main drainage canal in the eye, the 'Schlemms Canal'. If this 'sieve' becomes inelastic or degraded it inhibits the optimal flow of fluids to the drain. Imagine, if you will, a 'leaf-guard' on top of a gutter on the roof of your house.

Mannin's approach is to reduce IOP by addressing the defective cellular makeup of the actual 'drain or gutter' responsible for 70-90% of the fluid movement. Just a small improvement in the performance of this important vessel can have a significant effect on fluid movement and reducing IOP. So we believe this is a very important area for therapeutic development which is currently not being addressed with existing or new therapeutics in the pipeline.

The technical description of this is described in Dr. Quaggin's research published in the JCI 2014 paper (Thompson et all, JCI, 2014).

Q: Investorideas.com

In your recent update you stated it is your goal to have at least 3 asset transactions completed this year to expand and broaden your pipeline. Can you tell us what areas within your sector seem promising and what you are looking into?

A: Mr. Denis Corin, President of Q BioMed Inc.

We are not really looking in any area specifically. We are just hunting for good value in undervalued or undiscovered assets that we believe have great potential. That said, we have a few targets on our due diligence list now that we really like. The most likely to make the top of that short list is a revenue ready asset that we think could be a revenue generator in the first year and also has some very exciting indication expansion possibilities. We'd like to have one deal done in the next quarter and possibly one more by the end of the year.

We hope interested shareholders and potential shareholders will stay up to date on our progress and come along for the ride by visiting our website and sign up for out news updates.

About Q BioMed Inc. ( OTCQB : QBIO )

Q BioMed Inc. ("Q") is a biomedical acceleration and development company. We are focused on acquiring companies and biomedical assets. Q is dedicated to providing these target companies and assets, strategic resources, developmental support, and expansion capital to ensure they meet their developmental potential enabling them to provide products to patients in need.

http://qbiomed.com

About Investorideas.com - Big Ideas for Global Investors

InvestorIdeas.com - digital media global news source, PR and social media in leading sectors.

Follow Investorideas.com on Twitter  http://twitter.com/#!/Investorideas

Follow Investorideas.com on Facebook  http://www.facebook.com/Investorideas

Sign up for free news alerts at Investorideas.com

http://www.investorideas.com/Resources/Newsletter.asp

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp .

Disclosure: QBIO has retained investorideas.com for PR, media, news publication and social media effective February 5th for three months: two thousand five hundred per month.

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894 . Global investors must adhere to regulations of each country.

Contact Investorideas.com 800 665 0411

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Insider Risk Makes Human Judgment a Security Priority

Updated Category News Views 127

A badge, a password, and a locked gate can all look reassuring right up until the person holding them starts to crack. Signpost Six's new report, The Psychology of Insider Risk, lands on an uncomfortable truth: the most consequential security weakness may not be a system at all. It may be an employee under strain, in conflict, in debt, making a mistake, or being quietly...

Continue Reading
U.S. Patriot's Veteran Hiring Earns a Real National Nod

Updated Category News Views 5

A workforce award can be cheap wallpaper, but this one has some heft. U.S. Patriot, the veteran-founded and veteran-led military goods retailer owned by GALLS, landed on Military Times’ 2026 Best for Vets: Employers list, placing third in retail and first in Kentucky. The recognition covers 250 organizations, and this is U.S. Patriot’s fourth consecutive appearance....

Continue Reading
VeriSilicon's New AI/AR Glasses Tech: Game-Changer?

Updated Category News Views 271

VeriSilicon Unveils Next-Generation Subsystem There's some sizzle in the air with VeriSilicon's latest move in the wearable tech arena. They’ve launched a low-power, high-performance subsystem aimed squarely at AI and augmented reality glasses. Now, these gizmos aren't just the stuff of science fiction. Thanks to their Nano-XR series, reality might just get a splash...

Continue Reading
Ambition Links Call Scoring to the Coaching Room Faster

Updated Category News Views 13

A sales call dies twice when nobody turns the recording into practice. First it ends with the prospect, then it vanishes into a pile of transcripts, dashboards, and manager good intentions. Ambition’s new Call Intelligence feature is aimed squarely at that second failure. It brings Gong calls, transcripts, scorecards, and trackers into Ambition’s coaching workflow,...

Continue Reading
Trilith Holiday Tour Blends Film Access and Giving

Updated Category News Views 71

Snow machines, trolley rides, and a mental-health subsidy are sharing the same stage in Fayetteville this holiday season. That is an unusual mix, but it fits Trilith Foundation’s stated mission better than another generic lights-and-cocoa event ever could. From Nov. 21 through Dec. 31, the Foundation is turning its guided Trilith Studios tour into a seasonal experience...

Continue Reading
illumine Targets Childcare Chain Control and Risk Gaps

Updated Category News Views 30

Expansion Gets Messy Before It Gets Impressive Childcare operators do not usually stumble because they forgot how to care for children; they stumble because the back office fractures as the network grows. One center handles fees one way, another lets enrollment leads work a different funnel, and headquarters discovers too late that its reports are arguing with each other....

Continue Reading
Scribd’s First Safety Report Shows Enforcement at Scale

Updated Category News Views 292

Forty-seven million enforcement actions is not a decorative statistic Scribd finally put some hard numbers on a problem most document platforms prefer to discuss in foggy corporate language. Its first transparency report, covering January through June 2026, says the company took more than 47 million moderation actions across Scribd and Slideshare. That is a hulking...

Continue Reading
Skanska Adds $80M U.S. Tech Facility Contract to Orders

Updated Category News Views 107

An $80 million add-on is the sort of construction news that looks modest until you remember what it says about the customer relationship. Skanska has won an additional contract from an existing client for a U.S. tech facility, worth roughly SEK 760 million, and it will enter U.S. order bookings in the fourth quarter of 2026. No fireworks, no grand strategic...

Continue Reading
Inhibrx Ewing Data Gives Ozekibart a Real Clinical Signal

Updated Category News Views 165

Numbers this lopsided in relapsed Ewing sarcoma make me sit up straight, even after years of watching oncology releases try to turn every blip into a brass band. Inhibrx has reported updated Phase 1/2 data for ozekibart, paired with irinotecan and temozolomide, that look genuinely notable in a disease where patients have very few good cards left to play. That matters...

Continue Reading
Vuzix Bets on Lightweight Color Glasses for OEM Partners

Updated Category News Views 107

Forty grams is where this story gets interesting, because faces are ruthless product testers. People will tolerate plenty of clever technology right up until it pinches, looks goofy, leaks light, or makes them feel like they are wearing a science project. Vuzix is trying to clear that hurdle with Ultralite Color, a full-color AI eyewear reference platform built for OEM...

Continue Reading

Top 5 Most Recently Viewed Articles

Prinses Máxima Center Enhances Genomics with Callisto™ Innovation

Updated Category News Views 300

Prinses Máxima Center's Partnership with Volta Labs The Prinses Máxima Center for Pediatric Oncology is making headlines with its recent acquisition of the Callisto™ platform from Volta Labs. This major step forward aims to enhance efficiency in sample preparation across a variety of genomics workflows, specifically designed for both Illumina and Oxford Nanopore...

Continue Reading
Keros Therapeutics to Showcase Innovations at Key Conferences

Updated Category News Views 152

Exciting Participation of Keros Therapeutics in Major Conferences Keros Therapeutics, Inc. is making significant strides in the biopharmaceutical landscape by focusing on innovative therapies targeting disorders associated with the TGF-ß family of proteins. Recently, the company announced that its Chair and Chief Executive Officer, Jasbir S. Seehra, Ph.D., will represent...

Continue Reading
KULR Technology Unveils Major Licensing Breakthrough with Japan

Updated Category News Views 133

KULR Technology Group, Inc. (NYSE American: KULR) unveiled a major licensing agreement back in 2024 that had traders buzzing. This $2.35 million deal centered around their vibration reduction technology, known as KULR Xero Vibe (KXV). At first glance, it seemed like a solid step for the company into new markets, but let’s peel back the layers and see what's really...

Continue Reading
Mainz Biomed Achieves Significant Milestones and Results

Updated Category News Views 204

Mainz Biomed Reports Financial Results and Strategic Progress Lab network revenue up by 33% year-over-year. Operating loss down by 30% and net loss by 18%. Partnerships driving innovation and growth forward. Highlighting 2025 accomplishments and future goals. Mainz Biomed N.V. (NASDAQ: MYNZ), a pioneering molecular genetics diagnostic firm, has reported its financial...

Continue Reading
PioCreat Launches Innovative Mini Dental 3D Printer During Expo

Updated Category News Views 247

PioCreat Launches Innovative Mini Dental 3D Printer at Moscow Event PioCreat, a well-respected name in the 3D printing sector, made a significant impression at the dental industry's notable event, the 2025 Moscow Dental Expo. This gathering, renowned for showcasing advancements in digital dentistry, took place at Crocus-Expo IEC, attracting a wide array of international...

Continue Reading